文波,张彦燕,徐旖旎,杨光燕,陈妍,陶玲,沈祥春
WEN Bo,ZHANG Yanyan,XU Yini,YANG Guangyan,CHEN Yan,TAO Ling,SHEN Xiangchun

• 1:贵州医科大学天然药物资源优效利用重点实验室
• 2:贵州医科大学中药药理教研室
• 3:贵州医科大学

摘要(Abstract)：

目的:研究卡维地洛(CAR)对氧化低密度脂蛋白(ox-LDL)诱导的人主动脉内皮细胞(HAECs)损伤的保护作用。方法:体外培养HAECs,分为对照组、模型组、CAR高剂量组(CAR H组)和CAR低剂量(CAR L组),即对照组(无血清DMEM)、模型组(200 mg/L ox-LDL 100μL)、CAR高剂量组(CAR H组,200 mg/L oxLDL及1×10-5mol/L CAR各100μL)及CAR低剂量组(CAR L组,200 mg/L ox-LDL及1×10-6mol/L CAR各100μL),后两组CAR预保护1 h后,加入ox-LDL作用24 h;采用MTT法分析细胞存活率,吉姆萨(Giemsa)染色后观察HAECs形态;酶联免疫吸附法(ELISA)检测培养液中一氧化氮(NO)含量及乳酸脱氢酶(LDH)外漏量。结果:模型组与对照组相比,细胞发生严重的病理形态学改变,细胞存活率及NO含量显著降低,LDH外漏量显著升高(P<0.05),CAR H组和CAR L组细胞接近对照组,细胞存活率及NO含量较模型组显著提高,LDH外漏量显著降低(P<0.05)。结论:CAR能减少ox-LDL诱导的HAECs损伤,其作用可能与NO系统有关。
Objective: To investigate the protective effect of carvedilol(CAR) against oxidized low density lipoprotein( ox-LDL) induced human aortic endothelial cells( HAECs) injury. Methods:HAECs were cultured in vitro,randomly divided into four groups: control group( serum free DMEM),model group(200 mg / L ox-LDL 100 μL),carvedilol high dose group( CAR H group,200 mg / L oxLDL and 1 × 10-5mol / L CAR) and carvedilol low dose group( CAR L group,200 mg / L ox-LDL and1 × 10-6mol / L CAR). Two latter groups preincubated with carvedilol for 1 h and add ox-LDL for24 h; adopting MTT assay to analyze cell viability,HAECs morphology was observed by Giemsa staining. The contents of nitric oxide( NO) and the leakage of lactate dehydrogenase( LDH) were detected by enzyme-linked immunosorbent assay( ELISA). Results: Comparing model group with control group,cells underwent severe pathomorpholohy change,cell viability and NO content decreased significantly,LDH leakage increased significantly( P < 0. 05),cells of CAR H group and CAR L group were similar to control group,cell viability and NO content increased more than model group,LDH leakage decreased significantly( P < 0. 05). Conclusion: Carvedilol could ameliorate the HAECs injury induced by ox-LDL,which maybe involve in NO system.

关键词(KeyWords)： 卡维地洛;氧化低密度脂蛋白;主动脉;内皮,血管;氧化损伤
cardiavascular agents;carvedilol;oxidized low density lipoprotein;aorta;endothelium,vascular;oxidative injury

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(No.81360650);; 贵州省普通高等学校创新团队[黔教合人才团队字(2014)31];; 贵州省高层次创新性人才培养[黔科合人才(2015)4029号];; 大学生创新创业项目(No.201410660017);; 贵州省2011计划[黔教合协同创新字(2013)04];; 贵州省科技青年英才[黔省专合字(2012)161号]

作者(Author): 文波,张彦燕,徐旖旎,杨光燕,陈妍,陶玲,沈祥春
WEN Bo,ZHANG Yanyan,XU Yini,YANG Guangyan,CHEN Yan,TAO Ling,SHEN Xiangchun

DOI: 10.19367/j.cnki.1000-2707.2015.08.004

参考文献(References)：

• [1]王道艳,王志,张峥,等.齐墩果酸对ox-LDL诱导人脐静脉内皮细胞氧化损伤的保护作用[J].青岛大学医学院学报,2014(6):487-489.
• [2]Vogiatzig,Tousoulisd,Stefanadisc.The role of oxidative stress in atherosclerosis[J].Hellenic J Cardiol,2009(5):402-409.
• [3]吕铁伟,孙慧超,张蕾,等.ox-LDL抑制大鼠骨髓间充质干细胞的体外增殖和Oct-4表达[J].重庆医学,2014(14):1737-1740.
• [4]Chu L,Hao H,Luo M,et al.Ox-LDL modifies the behaviour of bone marrow stem cells and impairs their endothelial differentiation via inhibition of Akt phosphorylation[J].J Cell Mol Med,2011(2):423-432.
• [5]Charo I F,Taub R.Anti-inflammatory therapeutics for the treatment of atherosclerosis[J].Nat Rev Drug Discov,2011(5):365-376.
• [6]Kosior DA,Brodowski K,Krzykwa A,et al.Role of inflammation in etiology of atrial fibrillation-is lone arrhythmia really alone[J].Wiad Lek,2012(4):255-258.
• [7]刘淑萍.β受体阻滞剂在急性心肌梗死中的应用[J].中国老年学杂志,2013(12):2995-2998.
• [8]La Mura V,Colombo M.Bacterial translocation and nonselectiveβ-blockers in portal hypertension:Where we are,What still we need[J].Gastroenterology,2014:Epub ahead of print.
• [9]李露.β受体阻滞剂预防心力衰竭患者心脏性猝死的研究进展[J].重庆医学,2012(17):1768-1771.
• [10]胡和生,闫素华.室性心律失常的交感神经机制诊疗进展[J].中华临床医师杂志:电子版,2013(23):10861-10863.
• [11]张健,魏欣冰,丁华,等.卡维地洛对过氧化氢致血管内皮细胞氧化应激损伤的保护作用[J].中国药理学通报,2006(5):620-624.
• [12]张霞,金惠敏.慢性肾脏病与血管内皮细胞功能的研究进展[J].上海交通大学报,2012(4):528-532.
• [13]薛建峰,赵成军,贾如意.血管内皮损伤标志物[J].医学综述,2006(8):461-463.
• [14]邱雅慧.血管内皮细胞的功能以及损伤修复与动脉粥样硬化[J].中国组织工程研究与临床康复综述,2007(11):1927-1929.
• [15]王桂霞.血管内皮细胞损伤机制及其药物保护作用的研究进展[J].辽宁医学院学报,2008(5):466-468.
• [16]Grassi D,Desider G,Ferri C.Cardiovascular risk and endoendithelial dysfunction:the preferential route for athersosclerosis[J].Curr Pharm Biotechnol,2011(9):1343-1353.

文章评论(Comment)：